Skip to main content

Market Overview

The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors


The Medicines Company (NASDAQ: MDCO) announced on Wednesday that it has appointed Dr. Alexander Denner to its Board of Directors.

Denner is the Chief Investment Officer of Sarissa Capital Management, a registered investment advisor. Denner founded the firm in 2012 and prior to that he was a Senior Managing Director at Icahn Capital.

According to Whale Wisdom, Sarissa Capital Management is a major shareholder of The Medicines Company as it owns 1.567 million shares.

Denner also serves as a director of Biogen Inc (NASDAQ: BIIB) and Chairman of Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA).

"We are very pleased to have Alex join the Board," said Dr. Fredric Eshelman, Chairman of The Medicines Company's Board. "His broad range of experience as a healthcare investor and director, as well as in overseeing the operations and R&D of healthcare companies, will be a tremendous asset to The Medicines Company. We look forward to drawing on Alex's expertise as we continue to execute on our plan."

"Alex has been supportive of The Medicines Company for many years and I am delighted to welcome Alex to the Board," said Dr. Clive Meanwell, Chief Executive Officer. "Alex will no doubt provide valuable insight and guidance as we continue to take decisive actions for the benefit of all shareholders."

Shares of The Medicines Company were trading higher by around 1 percent mid-Wednesday afternoon.


Related Articles (ARIA + BIIB)

View Comments and Join the Discussion!

Posted-In: Alexander Denner Clive Meanwell Fredric Eshelman Icahn Capital Sarissa Capital Management The Medicines CompanyNews Management

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at